Home » Stocks » MNPR

Monopar Therapeutics, Inc. (MNPR)

Stock Price: $6.60 USD -0.21 (-3.08%)
Updated Jan 27, 2021 1:13 PM EST - Market open
Market Cap 78.33M
Revenue (ttm) n/a
Net Income (ttm) -5.38M
Shares Out 11.12M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $6.60
Previous Close $6.81
Change ($) -0.21
Change (%) -3.08%
Day's Open 6.81
Day's Range 6.51 - 6.72
Day's Volume 24,812
52-Week Range 4.36 - 19.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 4 weeks ago

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

-Issued patent expands and strengthens Monopar's existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 

GlobeNewsWire - 1 month ago

WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase p...

GlobeNewsWire - 1 month ago

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

GlobeNewsWire - 2 months ago

Validive ® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021

GlobeNewsWire - 2 months ago

Strengthens Monopar's Validive IP Portfolio To 2035 Strengthens Monopar's Validive IP Portfolio To 2035

GlobeNewsWire - 4 months ago

WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate u...

GlobeNewsWire - 4 months ago

WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly develop...

GlobeNewsWire - 5 months ago

WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (B...

InvestorPlace - 5 months ago

Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.

Other stocks mentioned: CARS, F, INVE, KGC, LIVX, LLNW, TEVA
InvestorPlace - 5 months ago

With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.

Other stocks mentioned: ACI, HD, LULU, MMM, SQM, SWBI, TDOC, WPM
GlobeNewsWire - 5 months ago

Potential Companion Diagnostic to Monopar’s uPRIT Program Potential Companion Diagnostic to Monopar’s uPRIT Program

GlobeNewsWire - 5 months ago

WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloi...

GlobeNewsWire - 5 months ago

Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Tec...

GlobeNewsWire - 6 months ago

CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that ...

Benzinga - 7 months ago

Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher on Tuesday, after the company announced it joined forces with NorthStar to develop a radio-immuno-therapeutics to target severe co...

About MNPR

Monopar Therapeutics, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal a... [Read more...]

Industry
Biotechnology
IPO Date
Dec 19, 2019
CEO
Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
MNPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is 30.33, which is an increase of 359.55% from the latest price.

Price Target
$30.33
(359.55% upside)
Analyst Consensus: Buy